Skip to content

Effects of SGLT2 Inhibitors on Fatigue Symptoms and Quality of Life in Patients with Diabetic Kidney Disease

Effects of SGLT2 Inhibitors on Fatigue Symptoms and Quality of Life in Patients with Diabetic Kidney Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121725
Enrollment
Unknown
Registered
2026-04-02
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease (DKD)

Interventions

Observation group:None

Sponsors

The Second Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 75 years, male or female; 2.Patients diagnosed with diabetic kidney disease (diabetes complicated with chronic kidney disease, with diabetes diagnosis based on the World Health Organization definition and chronic kidney disease according to the 2024 KDIGO guidelines); 3.Patients who have not previously used SGLT2 inhibitors and currently require treatment with an SGLT2 inhibitor(Janagliflozin). 4.Patients self-reporting fatigue (with a baseline FACIT-F scale score = 40); 5.Patients voluntarily signing written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with fatigue caused by other diseases (such as thyroid dysfunction); 2.Patients complicated with severe heart failure (NYHA class III-IV), advanced liver disease, or active tumors; 3.Patients with a history of recurrent genitourinary tract infections (>=3 times in the past year); 4.Female patients who are pregnant or planning pregnancy within the next 6 months; 5.Patients unable to complete the questionnaire due to cognitive impairment or language barriers.

Design outcomes

Primary

MeasureTime frame
The hs-CRP;Glycosylated hemoglobin, HbA1c;Fasting blood glucose, FPG;Oxidized low-density lipoprotein, ox-LDL;Neutrophil/lymphocyte ratio, NLR;Interleukin-6, IL-6;Platelet/lymphocyte ratio, PLR;

Countries

China

Contacts

Public ContactXiaoming Chen

The Second Affiliated Hospital of Guangdong Medical University

cxmgood@126.com+86 759 2387612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026